Meeting
2024 ASCO Genitourinary Cancers Symposium
Clinical efficacy of lurbinectedin in metastatic neuroendocrine carcinomas of the genitourinary tract: Multi-institutional real-world experience.
Authors
Mohammad Jad Moussa
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Mohammad Jad Moussa , Syed Arsalan Ahmed Naqvi , Jaanki Khandelwal , Matthew T Campbell , Ana Aparicio , Bilal Ahmed Siddiqui , Alan Haruo Bryce , Parminder Singh , Omar Alhalabi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 601)
DOI
10.1200/JCO.2024.42.4_suppl.601
Abstract #
601
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.
First Author: Yasunobu Ishizuka
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer.
First Author: Dongmei Ji